Atria Wealth Solutions Inc. Sells 107 Shares of Lam Research Co. (NASDAQ:LRCX)

Atria Wealth Solutions Inc. decreased its stake in Lam Research Co. (NASDAQ:LRCX) by 1.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,483 shares of the semiconductor company’s stock after selling 107 shares during the period. Atria Wealth Solutions Inc.’s holdings in Lam Research were worth $6,658,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Orion Capital Management LLC bought a new stake in Lam Research in the third quarter worth $25,000. BluePath Capital Management LLC purchased a new position in shares of Lam Research during the 3rd quarter worth $28,000. OFI Invest Asset Management purchased a new stake in Lam Research during the third quarter worth about $30,000. Asset Dedication LLC boosted its holdings in Lam Research by 56.7% in the third quarter. Asset Dedication LLC now owns 47 shares of the semiconductor company’s stock valued at $30,000 after purchasing an additional 17 shares in the last quarter. Finally, Valued Wealth Advisors LLC purchased a new stake in shares of Lam Research during the fourth quarter worth approximately $30,000. 84.61% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lam Research

In other news, SVP Seshasayee Varadarajan sold 5,500 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $922.41, for a total value of $5,073,255.00. Following the sale, the senior vice president now directly owns 22,095 shares of the company’s stock, valued at approximately $20,380,648.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Seshasayee Varadarajan sold 5,500 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $922.41, for a total transaction of $5,073,255.00. Following the sale, the senior vice president now directly owns 22,095 shares of the company’s stock, valued at $20,380,648.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Christina Corrreia sold 647 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $972.03, for a total transaction of $628,903.41. Following the sale, the chief accounting officer now directly owns 5,541 shares in the company, valued at $5,386,018.23. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,029 shares of company stock worth $6,559,489. 0.32% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on LRCX shares. Barclays raised their price target on Lam Research from $825.00 to $865.00 and gave the stock an “equal weight” rating in a research note on Thursday. B. Riley raised Lam Research from a “neutral” rating to a “buy” rating and upped their price target for the company from $870.00 to $1,100.00 in a research report on Friday, April 19th. Evercore ISI assumed coverage on Lam Research in a report on Tuesday, April 16th. They issued an “outperform” rating and a $1,200.00 target price for the company. Raymond James lifted their target price on Lam Research from $850.00 to $950.00 and gave the stock an “outperform” rating in a report on Thursday, January 25th. Finally, UBS Group increased their target price on Lam Research from $1,130.00 to $1,150.00 and gave the stock a “buy” rating in a research note on Thursday. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $950.85.

Lam Research Price Performance

Shares of LRCX stock traded up $14.10 on Friday, hitting $915.57. 67,600 shares of the stock traded hands, compared to its average volume of 1,059,003. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.06 and a quick ratio of 2.02. The firm has a market cap of $120.03 billion, a price-to-earnings ratio of 33.15, a PEG ratio of 3.20 and a beta of 1.51. The firm has a 50 day simple moving average of $943.68 and a two-hundred day simple moving average of $807.04. Lam Research Co. has a 52 week low of $493.42 and a 52 week high of $1,007.39.

Lam Research (NASDAQ:LRCX) last posted its quarterly earnings results on Wednesday, April 24th. The semiconductor company reported $7.79 EPS for the quarter, beating the consensus estimate of $7.26 by $0.53. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.72 billion. Lam Research had a net margin of 25.35% and a return on equity of 45.76%. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.99 EPS. As a group, equities research analysts predict that Lam Research Co. will post 28.96 earnings per share for the current fiscal year.

Lam Research Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 3rd. Shareholders of record on Wednesday, March 13th were paid a dividend of $2.00 per share. The ex-dividend date of this dividend was Tuesday, March 12th. This represents a $8.00 dividend on an annualized basis and a yield of 0.87%. Lam Research’s payout ratio is 29.42%.

Lam Research Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.